Metabolism and toxicity of metribuzin in mouse liver

Metribuzin was hepatotoxic in mice when administered intraperitoneally (ip) at sublethal doses of 150 to 250 mg/kg. Four dose-dependent abnormalities were evident. Histopathological examination revealed a fulminant centrilobular hepatic necrosis. The serum glutamic-pyruvic transaminase (GPT) activity was elevated. The liver glutathione (GSH) content was almost completely depleted. There was extensive covalent binding of radiocarbon from carbonyl-¹⁴C]metribuzin to liver proteins and also high blood levels of metribuzin fragments. Each of these four effects of metribuzin on the liver or blood was alleviated or blocked in mice pretreated with piperonyl butoxide (PB), which inhibits the cytochrome P-450-dependent monooxygenase. PB also reduced the lethality of metribuzin by three-fold. In contrast, pretreatment with diethyl maleate to suppress the liver GSH content increased the lethality of metribuzin by twofold. The hepatotoxicity and acute lethality of metribuzin were probably due to reactive intermediates which are normally detoxified by GSH conjugation. The principal urinary metabolites of metribuzin in mice and rats are mercapturic acids, which arise via metribuzin sulfoxide or deaminometribuzin sulfoxide reacting with GSH. Sulfoxidation therefore appears to activate metribuzin to an electrophilic metabolite which, in the absence of GSH, binds to tissue proteins producing hepatotoxicity.